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ABSTRACT
Monocarboxylate Transporter 2 (MCT2) is a major pyruvate transporter encoded 
by the SLC16A7 gene. Recent studies pointed to a consistent overexpression of MCT2 
in prostate cancer (PCa) suggesting MCT2 as a putative biomarker and molecular 
target. Despite the importance of this observation the mechanisms involved in 
MCT2 regulation are unknown. Through an integrative analysis we have discovered 
that selective demethylation of an internal SLC16A7/MCT2 promoter is a recurrent 
event in independent PCa cohorts. This demethylation is associated with expression 
of isoforms differing only in 5’-UTR translational control motifs, providing one 
contributing mechanism for MCT2 protein overexpression in PCa. Genes co-expressed 
with SLC16A7/MCT2 also clustered in oncogenic-related pathways and effectors of 
these signalling pathways were found to bind at the SLC16A7/MCT2 gene locus. 
Finally, MCT2 knock-down attenuated the growth of PCa cells. The present study 
unveils an unexpected epigenetic regulation of SLC16A7/MCT2 isoforms and identifies 
a link between SLC16A7/MCT2, Androgen Receptor (AR), ETS-related gene (ERG) 
and other oncogenic pathways in PCa. These results underscore the importance of 
combining data from epigenetic, transcriptomic and protein level changes to allow 
more comprehensive insights into the mechanisms underlying protein expression, 
that in our case provide additional weight to MCT2 as a candidate biomarker and 
molecular target in PCa.
INTRODUCTION
Prostate cancer (PCa) is the third leading cause of 
cancer death in developed countries and the most common 
cancer in men and involves a challenging diagnosis [1]. 
Recent studies point to a consistent overexpression of 
Monocarboxylate Transporter 2 (MCT2) in PCa [2, 3], 
which, in terms of sensitivity and specificity to detect 
malignant glands was comparable to Alpha-Methyacyl-
CoA-Racemase (AMACR) an established prostate cancer 
biomarker. This raises the possibility that MCT2 could 
have an important functional role in PCa disease [2]. 
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MCT2 has the highest affinity for pyruvate and lactate of 
all the functionally characterized MCTs being a primary 
pyruvate transporter in man [4, 5]. In human cancers 
MCT2 has been described to be strongly expressed in the 
cytoplasm of colorectal cancer cells indicating a possible 
role in intracellular organelles such as mitochondria [6]. 
Also, MCT2 is the primary isoform expressed in human 
glioblastoma multiform and glioma-derived cell lines [7]. 
A more recent study in colorectal cancer described that 
MCT2 knockdown suppressed KRAS mutant colorectal 
tumour growth in vivo, indicating MCT2 as a promising 
target in colorectal cancer [8].
Despite the recent observation of MCT2 expression 
in PCa tumours the mechanisms of over-expression 
remains unknown and it is not known if this expression is 
maintained across different stages of the disease. Also, the 
impact of MCT2 inhibition in PCa cells is still unknown 
and links between SLC16A7/MCT2 and major prostate 
cancer drivers such as Androgen Receptor (AR) ETS-
related genes (ERG) have not previously been studied. In 
this study we propose a rationale for the increase of MCT2 
expression through an integrative analysis of epigenetic, 
transcriptome and protein level data from prostate cancer 
tissue and unveil a link between SLC16A7/MCT2 and 
major oncogenic pathways in prostate cancer.
RESULTS
A selective demethylation at the SCL16A7 locus 
occurs in PCa compared to benign tissue
In a cohort of four PCa tumours with matched non-
malignant tissue we found two differentially methylated 
regions (DMRs) at the SLC16A7 locus. At the promoter 
upstream of the full-length SLC16A7/MCT2 isoform 
we observed an increase in DNA methylation in prostate 
tumours (DMR1) and at an internal, alternative promoter 
for SCL16A7/MCT2 locus (DMR2) we observed recurrent 
demethylation in PCa compared to benign tissue, both 
within and between patients (Figure 1A-1B). Analysis of 
methylation profiling from a large cohort of PCa tumours 
(n = 304) showed that demethylation at the internal 
SLC16A7/MCT2 promoter region and hypermethylation 
at the upstream promoter is a recurrent and significant 
change in PCa tumours (Wilcox test p < 0.001; Figure 1A-
1B). These differentially methylated regions (DMRs) at the 
SLC16A7/MCT2 locus mapped to a promoter upstream 
of full-length SLC16A7/MCT2 (DMR1) and an internal 
promoter region (DMR2, Figure 1C). RNA-sequencing 
analysis revealed a switch in SLC16A7/MCT2 isoform 
expression between benign and PCa tumours, defined by 
repression of the full-length SLC16A7/MCT2 isoform and 
maintained expression of an alternative isoform arising 
from an internal promoter (Figure 1D-1E), consistent 
with the reciprocal DNA methylation changes observed. 
These alternative isoforms of SLC16A7/MCT2 contain 
identical coding sequences and differ only in their 5’-UTR 
sequences (Figure 1C), analysis of which revealed key 
differences in motifs governing translational mechanisms 
between the isoforms expressed in tumour and benign 
prostate samples (Figure 1F). Together these findings 
suggest that selective methylation and demethylation 
occurs in prostate tumours at two distinct promoter regions 
within the SLC16A7/MCT2 locus, resulting in expression 
of an alternative isoform containing a different set of 5’-
UTR translation signals. This acquired epigenetic change 
therefore represents one possible mechanism responsible 
for the robust increase of MCT2 protein expression 
observed in prostate tumours. 
Immunohistochemical staining for MCT2 in human 
prostate tissue confirmed intense staining in tumour glands 
and low or absent staining in adjacent benign glands 
(Figure 1G). Also, 7 out of the 10 PCa bone metastasis 
analysed were positive for MCT2 expression (Figure 
1H), showing for the first time the presence of MCT2 
expression in metastatic prostate cancer.
MCT2 expression persists in hormone-refractory 
disease and SLC16A7/MCT2 is strongly linked 
with ERG 
The AR and its fusion-gene target TMPRSS2-ERG 
are important regulators of oncogenic pathways in prostate 
cancer cells [9-11]. We sought to elucidate the potential 
cross-regulation between MCT2 and AR signalling. We 
found both AR and ERG binding sites at the SLC16A7/
MCT2 locus from ChIP-sequencing of PCa cell lines 
(Figure 2A). Notably we found evidence of ERG binding 
at the main SLC16A7/MCT2 promoter in VCaP cells [10] 
and also a distinct pattern of AR binding at a downstream 
enhancer in this TMPRSS2-ERG fusion positive PCa 
cell line (Figure 2A) [11-13]. ERG knock-down affected 
the expression of both long and short SCL16A7/MCT2 
isoforms in VCaP cells, but with different dynamics 
(Figure 2B-2C) [14]. However ERG depletion showed 
little effect on signal for SLC16A7/MCT2 3’-UTR 
sequences suggesting either selective regulation of specific 
isoforms by ERG or that other factors dominate in the 
regulation of levels of transcripts containing these 3’-UTR 
sequences (Figure 2B-2E). 
Consistent with this observation of AR binding sites 
at the SLC16A7/MCT2 locus we also found that castration 
of PCa xenografts (thereby blocking AR signalling) affects 
MCT2 transcript levels, particularly for the long SLC16A7 
isoform (Figure 2F-2G). However, probes detecting the 
3’-UTR showed no change in response to modulation of 
AR signalling in PCa xenografts (Figure 2H), both in in 
vitro cultured cells (data not shown) or human tumours 
following AR blockade (Figure 2I), suggesting that AR 
Oncotarget21677www.impactjournals.com/oncotarget
Figure 1: A selective demethylation at the SCL16A7 locus occurs in PCa compared to benign tissue. A.-B. Boxplot 
summaries of DNA methylation at the SLC16A7/MCT2 gene locus showing results from (left panel) a cohort of prostatectomy specimens 
with multiple tumour cores (T1-4) and correspondent benign tissue and blood samples and (right panel) a cohort of 304 PCa tumours and 
49 benign samples (TCGA). Panel-A depicts data from the main SLC16A7/MCT2 promoter and panel-B depicts data from an alternative 
internal promoter site. P-values denote non-parametric Wilcox Rank Sum tests for each promoter region (above graphs) and for representative 
probes (probe name and P-value shown in graph). C. Genome browser view of the SLC16A7/MCT2 locus showing the median tumour/
normal methylation ratio for 304 TCGA prostate tumour samples (top, black line), expressed SLC16A7/MCT2 isoforms (top, red and blue), 
the location of the differentially methylated regions (DMR1 and DMR2) and expression array probe sets (bottom panel). D.-E. Boxplot 
showing expression of SLC16A7/MCT2 long D. and short E. isoforms in PCa tumour and benign tissues (TCGA RNA-seq). P-values 
denote non-parametric Wilcox Rank Sum tests. F. Summary of 5’-UTR motif analysis of the otherwise identical long (upper panel) and 
short (lower panel) isoforms of SLC16A7/MCT2. Showing occurrence and location of internal ribosome entry sites (IRES), gamma-IFN 
activated inhibitor of translation elements (GAIT), mTOR-regulated terminal oligopyrimidine tracts (TOP) and translation-inhibitor/stress-
related upstream open reading frame sequences (uORF). G. Immunohistochemical expression of MCT2 (100X) in prostate benign glands 
and prostate tumour glands. H. Immunohistochemical expression of MCT2 (200X) in prostate cancer bone metastasis (MET). 
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signalling effects on SLC16A7 expression are either 
context or isoform dependent. Finally, we observed strong 
MCT2 protein expression both in samples from patients 
treated with AR signalling blockade (Degarelix) and 
samples derived from patients with castrate resistant PCa 
(CRPCa) (Figure 2J). There was no significant change 
in MCT2 protein expression between AR blockade 
(Degarelix) treated and untreated PCa tumours, suggesting 
that any AR signalling effects on specific SLC16A7/
MCT2 isoforms do not impact on total MCT2 protein 
levels in the context of human PCa tumours. However, as 
observed in primary tumours, MCT2 protein expression 
was selectively increased in malignant tissue compared 
to adjacent non-neoplastic tissue and MCT2 expression 
persists in drug-resistant tumours (Figure 2J), suggesting 
that elevated MCT2 expression is maintained throughout 
PCa development from neoplasia to late stage, drug-
resistant tumours (Figure 2J), underscoring MCT2 as a 
Figure 2: MCT2 expression persists in hormone-refractory disease and SLC16A7/MCT2 expression is linked with 
the ETS-related gene ERG. A. Genome browser view of ChIP-Sequencing profiles of the AR and ERG transcription factors at the 
SLC16A7/MCT2 gene locus in LNCaP and VCaP cell lines. Short and long SLC16A7/MCT2 isoforms are shown, with ENCODE promoter 
and enhancer tracks. B.-E. Expression of SLC16A7/MCT2 in VCaP cells with and without ERG knock-down (GSE60771), probe-sets 
are coloured by the detected isoform using the colour scheme shown in Figure 1E. F.-H. Expression of SLC16A7/MCT2 in KuCaP PCa 
xenografts from full and castrated mice (GSE21887), again coloured by isoform. I. SLC16A7/MCT2 mRNA levels in patients untreated 
and treated with degarelix. J. Immunohistochemical expression of MCT2 in prostate tumours from patients treated with degarelix and in 
samples from patients with CRPCa (x200). 
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marker for malignant PCa and as a potential target for 
therapy.
 In silico analysis of SLC16A7/MCT2 association 
with prostate cancer phenotypes
To further examine the importance of SLC16A7/
MCT2 in PCa tumourigenesis we extended our analysis 
to microarray profiling datasets of PCa tissues available 
on the cBioportal database [15]. We clustered genes 
Figure 3: In silico validation of the role of SLC16A7/MCT2 expression in PCa aggressive behavior. A.-B. Expression 
profiles of SLC16A7/MCT2 co-expressed genes were obtained from The Cancer Genome Atlas (cBioportal) and clustered by functional 
role and signalling pathways using DAVID in silico tool. A. The panel represents the functional clusters organized by enrichment score 
and B. The panel represents the signalling pathway analysis. C. Venn diagram showing the overlap between genes expressed by CRC, 
glioma and PCa and associated with SLC16A7/MCT2 expression. A list of genes co-expressed with SLC16A7/MCT2 is represented. D. 
Genome browser view of the SLC16A7/MCT2 locus annotated with ENCODE ChIP-sequencing data for regulators linked to the signalling 
molecules found in Fig. 4C. Annotations are coloured by known links to EGFR/KRAS, PI3K/AKT or EMT signalling pathways. E. MCT2 
co-localizes with catalase at peroxisomes in PCa cells. MCT2 intracellular localization in PC3 cells, DAPI, MCT2, catalase and merged 
confocal image. Arrows indicate some of the co localization sites.
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co-expressed with SLC16A7/MCT2 (using probes 
common to SLC16A7/MCT2 isoforms) in prostate 
tissues available by their functional role and importance 
in signal transduction pathways using the DAVID 
bioinformatics tool (Figure 3A-3B) [16]. We found that 
the genes co-expressed with SLC16A7/MCT2 were 
functionally clustered in the categories of regulation 
of cell migration, response to wounding, inflammatory 
response, angiogenesis and apoptosis, all considered 
relevant for tumor progression and development (Figure 
3A). A sub-analysis by KEGG signalling pathways 
revealed that SLC16A7 co-expressed genes are grouped 
in pathways associated with PCa, colorectal cancer, renal 
cell carcinoma, leukemia, melanoma, glioma and mTOR 
signalling pathway among others (Figure 3B). We further 
explored the common MCT2 correlating genes between 
glioma, PCa and colorectal carcinoma (CRC), the only 
tumor types where MCT2 protein expression has been 
reported (Figure 3C). The core set of 13 genes common to 
these three tumor types included key regulators of major 
oncogenic pathways involved in tumor aggressiveness, 
including KRAS, EGF3 and PI3K (Figure 3C). The 
correlation of SLC16A7/MCT2 expression with these 
oncogenic signalling molecules in CRC, glioma and PCa 
indicates an association between oncogenic pathways 
and SLC16A7 gene expression. Using publicly available 
chromatin binding data sets we observed binding of 
several transcriptional regulators which lie downstream 
of EGFR, KRAS, PI3K and EMT signalling pathways 
(Figure 3D), providing tangible leads for future functional 
studies aiming to decipher the regulators of MCT2 in 
cancer. Finally, we observed a clear co-localization of 
MCT2 with Catalase (a well-known peroxisome marker, 
Figure 3E) confirming that in PCa MCT2 preferentially 
localizes at peroxisomes rather than mitochondria in 
prostate cancer cells [17].
MCT2 knock down affects cells kinetics and is 
correlated with EMT gene expression in human 
PCa tumours
The mRNA levels for MCT2 were readily 
detectable by qRT-PCR in prostate cell lines compared to 
immortalized normal prostate epithelial cells (PNT1A) and 
higher expression was observed at PC3 cells, the highly 
metastatic and androgen independent model (Figure 4A). 
To assess the functional importance of MCT2 in PCa 
cells we used RNAi knock-down and confirmed MCT2 
silencing using qRT-PCR three days after transfection 
(Figure 4B). We observed that MCT2 silencing caused a 
significant decrease in PCa cell proliferation, particularly 
for more aggressive PCa cell lines (Figure 4C). A 
significant increase in the proportion of cells in G0/
G1 was detected following MCT2 knock-down in PC3 
cells (Figure 4D), indicating that cell cycle arrest was a 
functional consequence of MCT2 silencing in PCa cells. 
Additionally, we observed that MCT2 knock-down caused 
a decrease in the expression levels of Vimentin (VIM) a 
major player in the epithelial-mesenchymal transition 
(EMT) process and involved in PCa invasiveness [18]; 
and transforming growth factor beta (TGFβ), which 
is associated with metastasis and poor survival in PCa 
[19]. In contrast the expression of NKX3.1, a prostatic 
tumor suppressor gene that is down-regulated in a large 
proportion of high-grade PCa, increased following 
MCT2 knock-down (Figure 4E). Finally, we found that 
the expression of several EMT markers correlated tightly 
with MCT2 expression in PCa tumours (r2 > 0.8; Figure 
2F), consistent with our observation of VIM and TGFB 
depletion in PCa cell lines following MCT2 knock-down 
and suggesting a link between MCT2 and EMT signalling 
pathways. Additionally, we observed a significant decrease 
in extra-cellular acidification rates (ECAR) after MCT2 
inhibition and an increase in oxygen consumption rates 
(OCR) (Figure 4G-4H). These results highlight a non-
redundant metabolic role for MCT2 in prostate cancer 
cells and provide a functional explanation of the clinical 
relevance of MCT2 over-expression since it is well 
documented that an increase in extracellular acidification 
rates is linked with poor prognosis in cancer. In Figure 
4I we provide a schematic representation of SLC16A7/
MCT2 regulation and down-stream pathways in prostate 
cancer.
DISCUSSION
We report a selective demethylation of an 
internal promoter region within the SLC16A7/MCT2 
gene locus and a reciprocal hyper methylation of an 
upstream promoter region. These methylation changes 
are associated with differential expression in prostate 
tumours of an SLC16A7/MCT2 isoform that has an 
alternative 5’-UTR sequence containing alternative 
translation control elements. We observed the presence 
of AR and ERG binding sites at SLC16A7/MCT2 gene 
locus and found that these oncogenic transcription 
factors also had differential effects on SLC16A7/MCT2 
isoforms with alternative 5’-UTR sequences. The AR 
and its fusion-gene target ERG also regulate specific 
isoforms of the gene encoding MCT2 in PCa cells, 
although the ubiquitous over-expression of MCT2 protein 
throughout the disease course from primary tumours to 
CRPC suggests that these transcriptional regulators alone 
cannot account for the observed MCT2 over-expression 
in PCa. Importantly, genes co-expressed with SLC16A7/
MCT2 in human tumours also clustered in oncogenic-
related pathways (e.g. PI3K, EGFR, KRAS) and effectors 
of these signalling pathways were found to bind at the 
SLC16A7/MCT2 gene locus (e.g. MYC, EGR1, PRDM1). 
Therefore, we postulate that a combination of epigenetic 
changes and oncogenic signalling pathways converge on 
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Figure 4: MCT2 knock down affects cells kinetics and is correlated with EMT gene expression in human PCa tumours. 
A. mRNA expression levels of MCT2 respectively in prostate-derived cell lines determined by qRT-PCR. Data expressed as mean +/- SD 
(n = 3). (***p < 0.001). B. LNCaP, 22RV1 and PC3 cells were transfected with two different combinations of siRNA (siRNA #1 and siRNA 
#6) directed against MCT2. Successful knock-down was validated using qRT-PCR three days after transfection. Data expressed as mean 
+/- SD (n = 4). C.-E. Effects of MCT2 knock-down on cell growth. C., Effect of MCT2 knock-down (siMCT2) in a panel of prostate 
cancer cell lines compared to the untreated cells (UT) after 48h (***p < 0.001). D., Percentage of PC3 cells in G0/G1, S and G2/M fraction 
when MCT2 is silenced compared to control cells (UT). Data expressed as mean +/- SD (n = 3). (***p < 0.001). E. To assess effects of 
MCT2 knock down in genes associated with poor prognosis in PC, PC3 cells were transfected with siRNAs and grown for 3 days. mRNA 
expression was assessed by qRT-PCR; values are depicted relative to vehicle control for each siRNA. n = 4. F. Correlation analysis of 
SLC16A7/MCT2 in PCa tumour cohorts using cBioportal highlighted several EMT-related transcripts with strong correlations (R2 >  0.8) 
including TWIST2, BMP1, TGFB1 and TGFB2. G. Oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) H. are 
shown in control conditions (UT) and when MCT2 (siMCT2) is silenced in PC3 cells. I. Schematic representation of SLC16A7/MCT2 
regulation in prostate cancer.
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SLC16A7/MCT2 in prostate cancer cells to effect isoform 
switching and protein over-expression in PCa tumours. 
As previously suggested in liver cells [20] it is likely that 
MCT2 might be involved in a lactate pyruvate shuttle 
system across the peroxisomal membrane and to form, 
along with peroxisomal lactate dehydrogenase (pLDH), 
a peroxisomal lactate shuttle. MCT2 transporters within 
the peroxisome function to transport pyruvate into the 
peroxisome where it is reduced by pLDH to lactate. In 
turn, NADH is converted to NAD+, regenerating this 
necessary component for subsequent β-oxidation. Lactate 
is then shuttled out of the peroxisome via MCT2, where 
it is oxidized by cytoplasmic LDH (cLDH) to pyruvate, 
generating NADH for energy use and completing 
the cycle. MCT2 knock-down is likely to disrupt the 
metabolic balance at peroxisomes with implications for 
the proliferation rates of PCa cells and the activation of 
oncogenic pathways in PCa linked with the EMT process. 
Taken together the peroxisomal localization of MCT2 
and the decreased ECAR and increased OCR following 
MCT2 knock-down suggest that MCT2 inhibition alters 
flux of pyruvate/lactate into peroxisomes and a metabolic 
shift to oxidative phosphorylation. Recent studies have 
established a direct, functional interaction between 
peroxisomes and mitochondria raising the hypothesis that 
altered peroxisomal function could directly impact on 
mitochondria [21], providing one possible mechanism by 
which MCT2 may be acting in PCa cells.
MCT1 and MCT4 have been extensively described 
at the plasma membrane of solid tumours as major 
players in the acid-resistant phenotype of tumour cells 
[22, 23] and attractive targets for cancer therapy alone 
or in combination with other drugs targeting metabolism 
[24], MCT2 appears to contrast with this well-known 
and stablished function of MCTs 1 and 4 in glycolysis. 
The strong and cytoplasmic expression of MCT2 in 
prostate cancer cells not only sheds some light on the 
involvement of MCT2 in tumours that might not rely 
mainly on glycolytic metabolism, but also contributes to 
the understanding of particularities in the metabolism of 
prostate cancer cells that make it metabolically unique in 
comparison to other malignancies. These results provide 
a strong rationale for further studies of the role of MCT2 
in PCa and other tumor types, where it may provide new 
opportunities as either a biomarker for disease tissue or a 
therapeutic target similar to the recent developments for 
other members of the monocarboxylate transporter family.
MATERIALS AND METHODS
Patient’s samples
The present study was previously approved 
by Local Ethical Review Committee (ref. no. 
017/08-010-DEFI/015-CES). For patients exposed 
to degarelix treatment, informed written consent was 
received from participants prior to inclusion in the study 
under ethics committee number MREC 11/H0311/2. 
Full ethical approval was obtained for all elements 
of the study including clinical sample collection and 
analysis NCT01852864 (REC ref:11/H0311/2) and 
NCT00967889 (REC ref:01/4/061). 27 patients with 
high-risk PCa (PSA > 20ng/ml or Gleason grade > 7 or 
clinical stage ≥ cT2c) underwent radical prostatectomy 
were administered 240mg of degarelix S.C. (donated by 
Ferring pharmaceuticals) 7 days before undergoing radical 
prostatectomy. 10 metastatic PCa cases were obtained 
from clinical biopsy samples.
Immunohistochemistry (IHC) staining and 
analysis
IHC technique was performed according to the 
avidin biotin peroxidase complex principle (R.T.U 
Vectastain Elite ABC Kit [Universal], Vector Laboratories, 
Burlingame, CA), with the primary antibodies for MCT2 
(1:200, sc-14926, Santa Cruz). MCT2 expression, was 
analysed in prostate tissue samples using a combined 
score system. The evaluation was performed blindly by 
two independent observers that assessed the intensity and 
the extension of the staining as previously described [2, 3].
Confocal microscopy
For the immunofluorescence experiments the 
following antibodies were used: MCT2 (sc 14926, Santa 
Cruz Biotechnology), and catalase (ab88650, Abcam), 
and Alexa fluor 488, Alexa fluor 555 secondary antibodies 
(Invitrogen, Life Technologies).
Immunofluorescence analyses were performed in 
cells seeded in 8 well Ibidi slides (Thistle Scientific) fixed 
with 4 % paraformaldehyde in PBS, pH 7.4 for 20 min. 
Afterwards, cells were permeabilized with 0.2 % Triton 
X 100 for 10 min, blocked with 1 % BSA solution for 10 
min and incubated with primary (MCT2 and catalase) and 
respective secondary antibodies for 1 h each. Cells were 
washed in PBS, incubated 10 minutes with Hoescht 33342 
stain washed again and digital images recorded using a 
Leica TCS SP5 confocal microscope Leica, Germany). 
siRNA transfection
siRNA for MCT2 was purchased from Qiagen (Hs_
SLC16A7_1, siRNA SI00720531 and Hs_SLC16A7_6, 
siRNA SI04191348) and transfected using Lipofectamine 
RNAiMAX (Invitrogen) according to the manufacturer’s 
reverse transfection protocol. Unless otherwise indicated, 
final siRNA concentrations of 10 nM were used.
Oncotarget21683www.impactjournals.com/oncotarget
Statistical analysis
Data from human tissue samples were analysed with 
SPSS statistical software (version 18.0; SPSS) using the 
Pearson’s χ² test, with the threshold for significance being 
p ≤ 0.05. For in vitro studies, GraphPad prism 5 software 
was used, with the Student’s t-test, considering significant 
values to be p ≤ 0.05. 
In silico analysis
Illumina 450k DNA methylation profiling data 
were retrieved from the ArrayExpress portal (accession 
E-MTAB-2964) and TCGA data-portal (PCa tumour 
and benign data). Expression data were retrieved from 
the TCGA data-portal (PCa tumour and benign RNA-
seq isoform level data) or from the Gene Expression 
Omnibus (GEO, accessions: GSE60771, GSE21887). 
Chomatin immunoprecipitation data were retrieved from 
publications (as cited) and ENCODE data were accessed 
through the UCSC Genome Browser. Data processing and 
analysis were performed using the R-statistical software 
and Bioconductor packages [25] . 
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